Corporate
Jun. 15, 2017 biOasis Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities
VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) announced today it has engaged FreeMind Group to assist the Company pursue non-dilutive funding opportunities globally. The biOasis Transcend technology has been demonstrated to transport several different drug modalities (e.g., antibodies, enzymes, small molecules) across the blood-brain barrier (BBB) and into the central nervous system (CNS). The… Read more »
May. 16, 2017 biOasis Announces the Engagement of Mackie Research to Provide Market Making Services
VANCOUVER, British Columbia–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”), is pleased to announce that, subject to regulatory approval, it has retained Mackie Research Capital Corporation (“Mackie Research”) to initiate its market making service to provide market making services to the Company in compliance with the policies and guidelines of the TSX Venture Exchange… Read more »
Apr. 24, 2017 biOasis Announces Investor Relations Service Agreement
VANCOUVER, British Columbia–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”) The Company announces that it has entered into an investor relations agreement (“Agreement”) with 551943 Alberta Ltd., operating as Colwell Capital Corp (“Colwell”), for a maximum term of twelve months commencing April 24, 2017. The Company will pay Colwell $4,000 per month and will… Read more »
biOasis Appoints Mark Day, Ph.D., as Chief Executive Officer and Director
VANCOUVER, British Columbia–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”) has appointed Mark Day, Ph.D., as President and Chief Executive Officer of the Company, effective immediately. Dr. Day succeeds Mr. Rob Hutchison who will become Executive Chairman of the Board of Directors of the Company. Dr. Day will also serve on the biOasis Board… Read more »
Oct. 23, 2016 biOasis Engages Rising Tide Equity to Increase Global Awareness
VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today announced it has engaged Rising Tide Equity to increase its global awareness. Investors are increasingly using digital media and non-traditional media outlets to identify potential investment opportunities. Recent… Read more »
Sep. 20, 2016 biOasis Enters Into a License Agreement With Vaccinex Inc
Vancouver, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (“biOasis”), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, today announced it has entered into a License Agreement (the “Agreement”) with Vaccinex Inc. (“Vaccinex”). Under the terms of the Agreement, Vaccinex will have the right to commercialize its… Read more »
Jul. 10, 2016 biOasis Announces the Issuance of an Additional US Patent for The Delivery of Therapeutic Agents Across The Blood-Brain Barrier
Vancouver, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces the issuance of a US patent covering a refined subset of fragments found within Melanotransferrin or P97 for the delivery of therapeutic agents to the brain. The U.S.… Read more »
Apr. 21, 2016 biOasis Technologies Enters into a License Agreement with Astellas Research Institute of America LLC
Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI)(OTCQB: BIOAF)(the “Company”) announces that it has entered into a License Agreement to collaborate with Astellas Research Institute of America LLC (“Astellas”). The terms of the agreement, for competitive reasons, remain confidential, as do the specific therapeutic targets and work programs. The companies intend to collaborate on the… Read more »
Nov. 29, 2015 biOasis Announces the Issuance of a US Patent for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier Using Polypeptides Derived From the Transcend Protein Delivery Vector
Vancouver, BC–(Business Wire)– biOasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (“biOasis or the “Company), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (“BBB”), announces the issuance of a US patent covering the delivery of therapeutic agents by using polypeptides from the company’s Transcend BBB delivery vector. biOasis’ Transcend… Read more »
Nov. 11, 2015 biOasis Announces the Issuance of a Key US Patent for the Delivery Through the Blood-Brain Barrier of Therapeutic Antibodies – Inclusive of Trastuzumab – to Treat Her2/neu Brain Metastases
biOasis’ Transcend Platform has shown great utility in pre-clinical animal models to deliver therapeutic compounds into the brain at sufficient levels to reach a therapeutic effect. Without the Transcend delivery vehicle these compounds would otherwise be excluded from the brain due to the presence of the protective blood-brain barrier. The issuance of this patent indicates that compounds, such as in this case Trastuzumab can be, with the help of Transcend, protected under the issuance of a new patent, including for a new therapeutic indication – brain metastases. Trastuzumab coupled to the transport vector Transcend thus offers a potential treatment for this dreadful cancer.